A change advisory board holds vaccine-booking releases for three extra weeks even when the Increment is Done and the operational risk is low. What should the Product Owner partner toward?
Select an answer to reveal the explanation.
Short Explanation
A Done vaccine-booking Increment sitting in a three-week board queue is a bike with the kickstand still down. Blanket delay is not the same thing as managing risk. Partner toward risk-based release design so low-risk health value can go live.
Full Explanation
Organization-level release controls should scale with risk, not apply a uniform delay to every Increment. When a vaccine-booking Increment already meets the Definition of Done and residual risk is low, a change-advisory wait mainly harms Time-to-Market and empiricism. The Product Owner should partner on continuous, risk-based release design rather than expanding the board or transferring Product Backlog ownership to it. Annual freezes magnify the same problem.